CryoCath CE-marks 7F cardiac cryoablation device:
This article was originally published in Clinica
Executive Summary
Canada's CryoCath Technologies has CE-marked for sale in Europe its 7F Freezor catheter cryoablation system for treating cardiac tachyarrhythmias (rapid and irregular heartbeats). As well as being smaller and easier to handle than the company's earlier 9F Freezor product, which was CE-marked last year, the 7F system provides 40% more cooling capacity to treat tachyarrhythmias faster and more effectively, Steve Arless, CryoCath's president and CEO, told Clinica. The new product will be introduced into 20 leading centres this year, with a more widespread commercial launch planned for 2002, says the Kirkland, Quebec firm.